Compare Amphastar Pharmaceuticals Inc (AMPH) vs Dell Technologies Inc (DELL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Dell Technologies stock trades at $435.05, down 3.37% over the past day, but maintains a bullish technical outlook with strong support near $436. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $4.86 significantly exceeding the $2.96 forecast. Revenue for 2025 reached $95.57 billion with a net income margin of 6.28%, showing improved profitability. Recent news highlights include positive analyst coverage and political endorsements driving investor interest.

The outlook for Dell remains positive with analyst consensus pointing to 12% upside to the $487.06 price target. Key opportunities include AI server demand growth and expanding profit margins, while risks involve PC industry headwinds and competitive pressures. The stock's current valuation at 34.66 P/E requires continued earnings growth to justify further appreciation.